

ASX Release

Anatara receives \$1.23m R&D Tax Refund

BRISBANE, 18 January 2018: Anatara Lifesciences (ASX:ANR) is pleased to announce that it has received \$1,230,329 from the Australian Taxation Office under the Federal Government's Research and Development (R&D) Tax Incentive scheme.

The refund is from Anatara's 2016-2017 research activities and reflects a period of significant investment into the Company's lead product, Detach[®], for the control of gastrointestinal disease in pigs, as well as activities designed to progress Anatara's human therapeutics pipeline.

Anatara's Chairman and CEO, Dr Mel Bridges said, "The 2016-2017 period was an important one for Anatara as we focused on moving Detach closer to market and prepared to expand our program into human applications. The R&D tax incentive provides an important source of non-dilutive funding and enables the Company to remain well funded as we progress our commercialisation activities."

For more information please contact:

General inquiries	Media inquiries
Dr Mel Bridges Chairman & CEO, Anatara Lifesciences +61 (0) 413 051 600 mbridges@anatara.com	Jane Lowe Managing Director, IR Department +61 (0) 411 117 774 jane.lowe@irdepartment.com.au

About Anatara Lifesciences

Anatara Lifesciences is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach[®] is a natural plant based product that aids in the control of diarrhoea and will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called "super bugs" that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.

